Inventor
ONUOHA SHIMOBI
GB34 patents
⚠️ This page may combine multiple inventors who share the name “ONUOHA SHIMOBI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AUTOLUS LTD
27 patentsUS11091532B2Aug 17, 2021
T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
AUTOLUS LTD8 citations84
US11034750B2Jun 15, 2021
Chimeric antigen receptor (CAR) comprising a CD19-binding domain
AUTOLUS LTD8 citations84
US10981970B2Apr 20, 2021
Chimeric antigen receptor (CAR) comprising a CD22-binding domain
AUTOLUS LTD4 citations84
US11440961B2Sep 13, 2022
Anti TRBC1 antigen binding domains
AUTOLUS LTD7 citations83
US11434293B2Sep 6, 2022
Anti TRBC1 antigen binding domains
AUTOLUS LTD7 citations83
US10800854B2Oct 13, 2020
Chimeric cytokine receptors and encoding nucleic acids
AUTOLUS LTD6 citations83
US10800855B2Oct 13, 2020
Chimeric cytokine receptors and encoding nucleic acids
AUTOLUS LTD4 citations83
US12187769B2Jan 7, 2025
Cell
AUTOLUS LTD2 citations74
US11479613B2Oct 25, 2022
Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
AUTOLUS LTD1 citations72
US12049510B2Jul 30, 2024
Chimeric antigen receptor
AUTOLUS LTD2 citations71
US11590170B2Feb 28, 2023
Chimeric antigen receptor
AUTOLUS LTD3 citations71
US11180553B2Nov 23, 2021
Chimeric antigen receptor
AUTOLUS LTD4 citations71
US11466070B2Oct 11, 2022
Signalling system
AUTOLUS LTD2 citations69
US12398194B2Aug 26, 2025
Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface
AUTOLUS LTD0 citations62
US12234295B2Feb 25, 2025
Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
AUTOLUS LTD0 citations62
US11701386B2Jul 18, 2023
Cell
AUTOLUS LTD1 citations62
US11648274B2May 16, 2023
Polypeptide
AUTOLUS LTD0 citations62
US11479614B2Oct 25, 2022
Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
AUTOLUS LTD0 citations62
US12454578B2Oct 28, 2025
Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors
AUTOLUS LTD0 citations61
US12516119B2Jan 6, 2026
Anti TRBC1 antigen binding domains
AUTOLUS LTD0 citations60
US11963981B2Apr 23, 2024
Chimeric antigen receptor
AUTOLUS LTD0 citations60
US12492410B2Dec 9, 2025
Engineered cytolytic immunecell
AUTOLUS LTD0 citations59
US11945867B2Apr 2, 2024
T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody
AUTOLUS LTD0 citations57
US12241068B2Mar 4, 2025
CD79-specific chimeric antigen receptor
AUTOLUS LTD0 citations51
US12241124B2Mar 4, 2025
Molecular assessment of TRBC usage
AUTOLUS LTD0 citations46
US12325733B2Jun 10, 2025
Binding domain
AUTOLUS LTD0 citations45
US12496314B2Dec 16, 2025
Antigen-binding domain
AUTOLUS LTD0 citations44
IMMUNOQURE AG
5 patentsUS9475872B2Oct 25, 2016
Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
IMMUNOQURE AG5 citations81
US10131709B2Nov 20, 2018
Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
IMMUNOQURE AG4 citations70
US10081676B2Sep 25, 2018
Human anti-IL-32 antibodies and methods of making and using the same
IMMUNOQURE AG4 citations70
US10975144B2Apr 13, 2021
CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody
IMMUNOQURE AG0 citations60
US10875916B2Dec 29, 2020
Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
IMMUNOQURE AG0 citations49